(CRDF) Cardiff Oncology, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CRDF) Cardiff Oncology, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Cardiff Oncology, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy and shows how its marketing choices support positioning and sales. This page contains a real preview/sample of the analysis so you can review format and content; purchase the full version to get the complete ready-to-use report.
Product
Onvansertib lead asset
Onvansertib is Cardiff Oncology, Inc.'s lead therapeutic candidate and an oral, selective PLK1 inhibitor. It is being studied for anti-cancer use, including metastatic colorectal cancer, where PLK1 blockade aims to stop tumor cell division. In Cardiff Oncology's pipeline, this single asset carries most of the company's clinical and commercial value.
CY140 pipeline candidate
CY140 is Cardiff Oncology, Inc.’s PLK-family inhibitor, designed to hit PLK1, PLK2, and PLK3. The Company says it is in Phase 1/2 development in solid tumors and leukemias, which keeps the product tied to earlier-stage clinical risk. For investors, that means the asset’s value still hinges on human data, not sales, while the target set spans 3 PLK kinases.
TROV-054 combination study
TROV-054 is Cardiff Oncology, Inc.’s Phase 1b/2 combination study, evaluating the program with FOLFIRI plus bevacizumab in metastatic colorectal cancer. It fits the company’s oncology combo strategy, aiming to lift response versus standard doublet therapy. Cardiff Oncology, Inc. has not disclosed TROV-054 revenue yet, so the key value driver is clinical data, not sales.
TROV-053 prostate cancer trial
TROV-053 is in Phase II with Zytiga for metastatic castration-resistant prostate cancer, so Company Name is testing a late-stage proof-of-concept asset where response and safety can shape its next value step.
This combo targets a high-need market: prostate cancer is the 2nd most common cancer in U.S. men, with about 299,000 new cases and 35,000 deaths expected in 2025.
- Phase II, late-stage proof-of-concept
- Combo: Zytiga plus TROV-053
- mCRPC is a high-need setting
No approved marketed product
Cardiff Oncology, Inc. has no approved marketed product, so its Product mix is still all pipeline. It is a clinical-stage biotechnology company, and its value depends on trial data, regulatory progress, and cash runway rather than product sales.
As of the latest public reporting, Cardiff Oncology, Inc. remains in active development with zero commercial revenue from approved drugs. That makes clinical milestones the key value driver in 2026, not market share or product launches.
- No approved marketed product
- Clinical-stage portfolio only
- Value tied to trial outcomes
- No product sales revenue
Cardiff Oncology: Pipeline-Only, Onvansertib Leads
Cardiff Oncology, Inc. has no approved product, so Product is still pipeline-only in 2026. Onvansertib remains the lead asset, with CY140 and TROV combo studies adding early-stage depth. The mix is still driven by clinical data, not sales, and the company reported no product revenue in its latest filings.
| Metric | 2026/2025 |
|---|---|
| Approved products | 0 |
| Lead asset | Onvansertib |
| Product revenue | 0 |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Cardiff Oncology, Inc.’s product, pricing, place, and promotion strategy, grounded in real-world biotech positioning.
Editable Excel File
Simplifies Cardiff Oncology’s 4Ps into a quick, structured snapshot for faster strategic review and clearer team alignment.
Reference Sources
Provides a concise, traceable bibliography of industry reports, datasets, and benchmarks to speed due diligence and verify Cardiff Oncology’s key financial and market claims.
Place
San Diego headquarters
Cardiff Oncology, Inc. is based in San Diego, California, and the San Diego headquarters is its main corporate and scientific hub. It is the company’s primary business base, where strategy, research, and operations are anchored. For a clinical-stage oncology company, keeping leadership and science in one place helps speed decision-making and trial oversight.
Clinical trial site access
Cardiff Oncology, Inc. has no approved commercial product, so patients access its therapy only through clinical trial sites. That makes the trial network the company’s main distribution path, with enrollment, site reach, and investigator participation doing the work that pharmacies and wholesalers do for approved drugs. In practice, access depends on where studies are open and whether a patient qualifies for the protocol.
Hospital and oncology center network
Cardiff Oncology relies on oncology clinics and research hospitals for patient enrollment, dosing, and safety monitoring, so Place is really medical research infrastructure. In the U.S., more than 2,000 cancer centers and oncology practices help move patients into trials, which is why multi-site access matters for speed and data quality. Without that network, Cardiff Oncology cannot run studies at scale.
Development-stage supply chain
In 2025, Cardiff Oncology, Inc. had no retail supply chain; its investigational supply supports clinical trials for one lead drug, onvansertib. Manufacturing and logistics are sized to protocol demand and site enrollment, so batch timing stays small and variable, not store-driven. Availability depends on patient accrual and study cadence, not shelf stock.
- Trial-only supply, not commercial stock
- Batching follows protocol demand
- Enrollment drives availability
B2B scientific presence
Cardiff Oncology, Inc. reaches the market through the oncology research ecosystem, so its "place" is mainly B2B and site-based. In practice, that means investigators, study sponsors, and partner groups are the real access points, not retail channels. This fits a clinical-stage model where value is built inside trial sites and research networks, not in direct product distribution.
- Works through investigator-led study sites
- Targets sponsors and research partners
- Depends on oncology trial networks
Cardiff Oncology’s 2025 access stays trial-only, with no retail commercial channels
Cardiff Oncology, Inc. has no commercial retail "Place"; access runs through oncology trial sites and research hospitals. In 2025, its lead program, onvansertib, stayed investigational, so enrollment sites and investigator reach were the main access points. Distribution is trial-only, with supply sized to protocol demand.
| Place factor | 2025 data |
|---|---|
| Commercial channels | None |
| Lead program | Onvansertib |
| Access path | Clinical trial sites |
What You See Is What You Get
Cardiff Oncology, Inc. Reference Sources
The preview you see is the exact, full Cardiff Oncology, Inc. 4P's Marketing Mix analysis you'll receive immediately after purchase—complete, editable, and actionable for strategy or investor reporting.
Promotion
Clinical trial disclosure
Clinical trial disclosure is a key promotion channel for Cardiff Oncology, Inc. because trial registration and status updates on ClinicalTrials.gov show the program’s phase, indication, and design in real time. This kind of disclosure helps physicians, researchers, and investors track progress without waiting for a full paper. It also signals transparency, which matters when a drug like onvansertib is still moving through clinical development.
Investor relations communications
As a publicly traded biotech, Cardiff Oncology, Inc. uses press releases and investor updates to keep the market informed on pipeline progress and milestone events. These disclosures are central to showing clinical momentum, with 8-K, 10-Q, and presentation materials used to frame value for shareholders. In biotech, that steady IR cadence can move sentiment as much as product data.
Scientific conference visibility
Cardiff Oncology, Inc. fits scientific conference visibility well because oncology buyers expect efficacy and safety data at meetings like ASCO and ESMO. For a clinical-stage company, posters and oral talks are a direct way to show trial updates on onvansertib and build trust with oncologists and researchers.
Corporate website and filings
Cardiff Oncology, Inc. uses its corporate website and SEC filings to publish trial updates, risks, and strategy in one official place. Its latest 10-K and 10-Q filings give investors direct access to pipeline progress, cash use, and clinical milestones. This matters because clear, timely disclosure supports transparency and brand credibility.
- Official trial and pipeline updates
- Risk and strategy disclosure
- Supports investor trust
Rebranding to Cardiff Oncology
Cardiff Oncology, Inc. rebranded from Trovagene, Inc. in May 2012, making the oncology focus clear from the start. That name change sharpened brand positioning around cancer drug development and supports a long-term promotion strategy built on scientific identity, not legacy diagnostics. As of 2025, the brand has had 13 years to compound recognition in the oncology market.
Rebrand date: May 2012
Shifted identity to oncology
Built long-term brand clarity
Cardiff Oncology’s Clear, Trial-Driven Story
Cardiff Oncology, Inc. promotes mainly through trial disclosures, SEC filings, and conference data, so its message stays tied to onvansertib clinical progress. The company’s May 2012 rebrand from Trovagene, Inc. gave it a clearer oncology identity. That focus helps keep updates readable for physicians and investors.
| Promotion lever | Key fact |
|---|---|
| ClinicalTrials.gov | Real-time trial status |
| SEC filings | 10-K, 10-Q, 8-K updates |
| Conferences | ASCO, ESMO visibility |
| Rebrand | May 2012 oncology shift |
Price
No commercial price
Cardiff Oncology, Inc. has no marketed oncology product, so there is no public retail or reimbursement price. Its lead asset, onvansertib, is still in clinical development, and the Company reported 0 commercial product sales in its latest 2026/2025 period. With no approved product, pricing stays undefined until regulatory approval and launch.
Investigational access model
Cardiff Oncology, Inc. uses an investigational access model, so its therapies are priced inside clinical trials, not sold in the normal commercial market. That means there is no consumer price tag; value is set by trial design, site costs, and patient access, while the company remained pre-commercial with no drug sales as of its latest filings.
Development funding priority
Cardiff Oncology, Inc. is still in the development-funding phase, so cash is mainly directed to R&D and clinical trials, not product sales. That means its economic model is driven by trial spend, with pricing power tied to future approval and eventual commercialization. For investors, the key watch items are cash runway, burn rate, and trial milestones.
Future oncology pricing unknown
Cardiff Oncology, Inc. has not disclosed a commercial launch price, and all programs remain investigational. If any candidate wins approval, pricing will hinge on proven clinical benefit and payer access, especially in a market where oncology drugs often launch above $100,000 per year. Cardiff Oncology, Inc. reported no product revenue in its latest annual filings, so price remains a future, value-linked decision.
- No launch price disclosed
- Pricing depends on value and access
- All programs still investigational
Portfolio value before revenue
Cardiff Oncology, Inc. is valued mainly on pipeline progress, not sales, because it is still pre-commercial and has no product revenue in its latest filings. For a company like this, trial readouts, FDA steps, and deal news can move the portfolio value far more than unit price or margin math.
- Pre-revenue oncology model
- Value tracks trial milestones
- Partnerships can re-rate shares
- Margins matter less before launch
Cardiff Oncology Has No Sales Yet as Onvansertib Remains Pre-Commercial
Cardiff Oncology, Inc. has no approved oncology product, so there is no public launch price or reimbursement rate. In its latest 2026/2025 period, the Company reported 0 commercial product sales, and onvansertib remains investigational, so pricing will only matter after approval and payer access.
| Metric | 2026/2025 |
|---|---|
| Commercial product sales | 0 |
| Launch price | Not disclosed |
| Status | Pre-commercial |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.